0000014930-26-000027
SEC filingBrunswick Corporation (BC) reported FY 2025 net sales of $5.36B, with cost of sales at $4.03B, resulting in a gross profit of $1.33B. Operating earnings were negative at -$40.7M, impacted by $851.1M in SG&A, $168.7M in R&D, and significant $353.1M restructuring, exit, and impairment charges. Earnings before interest and taxes stood at -$35.3M, leading to earnings before income taxes of -$135.7M after $111.7M interest expense net of $7.2M interest income and $4.1M transaction charges. Net earnings from continuing operations were -$135.9M, with net loss from discontinued operations at -$1.4M, yielding total net loss of -$137.3M or -$2 per diluted share on 65.9M shares. Balance sheet shows total assets of $5.31B, current assets $2.06B including $256.8M cash, inventories $1.19B; current liabilities $1.43B; long-term debt $1.81B; shareholders' equity $1.63B. Operating cash flow from continuing operations was strong at $585.7M despite net loss, total OCF $562.1M, investing outflow -$141.6M, financing outflow -$441.2M, net cash decrease -$11.0M. No prior year figures disclosed.
Brunswick Corporation's FY 2025 10-K shows net sales of $5.36B and a significant net loss of -$137.3M, or -$2 per basic and diluted share based on 65.9M weighted average shares. Operating earnings were -$40.7M, pressured by $353.1M in restructuring, exit, and impairment charges, alongside $851.1M SG&A and $168.7M R&D expenses. Earnings before taxes reached -$135.7M after $111.7M interest expense, offset slightly by $7.2M interest income. Net earnings from continuing operations were -$135.9M, with additional -$1.4M loss from discontinued operations. Total assets stood at $5.31B, with shareholders' equity at $1.63B. No prior year comparisons are provided in the filing. Cash position includes $256.8M in cash equivalents. (148 words)
Net sales totaled $5.36B for the fiscal year ended 2025-12-31. No segment breakdowns, geographic revenue mix, or specific growth drivers are disclosed in the provided XBRL data or document content. Cost of sales was $4.03B. The filing does not provide year-over-year revenue changes or detailed revenue composition. (62 words)
Gross profit calculated as $5.36B net sales minus $4.03B cost of sales equals $1.33B, yielding a gross margin of 24.8%. Operating earnings of -$40.7M represent an operating margin of -0.8%. Key pressures included $353.1M restructuring charges, elevated SG&A at $851.1M (15.9% of sales), and R&D at $168.7M (3.1% of sales). No prior period margin comparisons available. (78 words)
Net cash provided by operating activities totaled $562.1M, with continuing operations at $585.7M despite the net loss, driven by $292.5M depreciation/amortization, $73.4M receivable improvement, and $96.8M accrued expenses increase, offset by -$114.3M inventory build. Investing activities used -$141.6M, mainly $165.8M capex. Financing used -$441.2M including $412.6M debt payments, $80.0M stock repurchases, and $112.6M dividends. Cash decreased $11.0M to $256.8M. Total debt $2.11B (short-term $295.4M, long-term $1.81B), current ratio supported by $2.06B current assets vs $1.43B current liabilities. (112 words)
No management guidance, strategic priorities, or specific risk factors are explicitly disclosed in the provided XBRL financial data or document content excerpts. The filing includes restructuring charges of $353.1M and asset impairment credits of -$323.2M in cash flow, indicating ongoing operational adjustments, but no forward-looking statements are present in the input. (68 words)